Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

May 19 2012

Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that an abstract reporting new data from the BiovaxID® Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with the significance of these results to be presented by the NCI at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012).    

The abstract (#2528), titled, "Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL)", is now available on-line at the ASCO website at: http://abstract.asco.org/AbstView_114_100528.html.

Biovest will further comment on these results following the NCI's presentation at ASCO on Saturday, June 2^nd in a poster presentation session from 8:00 am - 12:00 pm CST in Room S405, followed by a poster discussion session at 12:00 pm CST, also in Room S405, at the McCormick Place Convention Center in Chicago.

According to Biovest's President and CEO, Samuel S. Duffey, Esq., "The long-term commitment of the clinicians at the NCI to the potential of cancer vaccines to treat lymphoma is a tribute to the role of our federal government in the ongoing fight against cancer. BiovaxID was developed under a Cooperative Research and Development Agreement (CRADA) between Biovest and the NCI, and Biovest's ongoing progress is to a large degree due to the pioneering vision of NCI clinicians and their effort that has spanned almost two decades. We are indeed proud to have participated in such an important public/private partnership."